Soligenix Advances Rare Disease Pipeline, Focuses on HyBryte™ for CTCL

Ticker: SNGX · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 812796

Soligenix, Inc. DEF 14A Filing Summary
FieldDetail
CompanySoligenix, Inc. (SNGX)
Form TypeDEF 14A
Filed DateApr 29, 2024
Risk Level
Pages15
Reading Time18 min
Key Dollar Amounts$0.001
Sentimentbullish

Sentiment: bullish

Topics: Soligenix, HyBryte, CTCL, Clinical Trial, EMA

TL;DR

<b>Soligenix is progressing its HyBryte™ therapy for CTCL, securing EMA agreement on Phase 3 trial design while exploring strategic value-enhancing options.</b>

AI Summary

SOLIGENIX, INC. (SNGX) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Soligenix is advancing HyBryte™ (synthetic hypericin) as a potential treatment for cutaneous T-cell lymphoma (CTCL). The company received agreement from the EMA on key design components for a confirmatory Phase 3 clinical trial (FLASH2) for HyBryte™ in early-stage CTCL patients. The FLASH2 trial will replicate the double-blind, placebo-controlled design of the successful Phase 3 FLASH study. Discussions with the FDA regarding the confirmatory Phase 3 trial design are ongoing. Soligenix is evaluating strategic options to increase stockholder value, including M&A opportunities.

Why It Matters

For investors and stakeholders tracking SOLIGENIX, INC., this filing contains several important signals. The agreement with the EMA on the FLASH2 trial design is a critical step towards potential worldwide marketing approval for HyBryte™ in CTCL. The company's commitment to exploring M&A opportunities signals a proactive approach to maximizing shareholder value, especially given the complexities of drug development.

Risk Assessment

Risk Level: — SOLIGENIX, INC. shows moderate risk based on this filing. The company's success hinges on the ongoing FDA discussions and the eventual outcome of the confirmatory Phase 3 trial, which carries inherent clinical and regulatory risks.

Analyst Insight

Monitor FDA feedback on the Phase 3 trial design and track progress on the FLASH2 study enrollment and results.

Key Numbers

  • 2024-04-30 — Proxy Statement Date (Date of the filing)
  • 2024-05-23 — Conformed Period of Report (Period the filing pertains to)

Key Players & Entities

  • SOLIGENIX, INC. (company) — Filer name
  • HyBryte™ (drug) — Potential treatment for CTCL
  • cutaneous T-cell lymphoma (CTCL) (disease) — Target indication for HyBryte™
  • U.S. Food and Drug Administration (FDA) (regulator) — Agency involved in trial design discussions
  • European Medicines Agency (EMA) (regulator) — Agency that agreed on trial design components
  • FLASH2 (trial) — Confirmatory Phase 3 study name
  • FLASH (trial) — Previous Phase 3 study name

FAQ

When did SOLIGENIX, INC. file this DEF 14A?

SOLIGENIX, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by SOLIGENIX, INC. (SNGX).

Where can I read the original DEF 14A filing from SOLIGENIX, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by SOLIGENIX, INC..

What are the key takeaways from SOLIGENIX, INC.'s DEF 14A?

SOLIGENIX, INC. filed this DEF 14A on April 29, 2024. Key takeaways: Soligenix is advancing HyBryte™ (synthetic hypericin) as a potential treatment for cutaneous T-cell lymphoma (CTCL).. The company received agreement from the EMA on key design components for a confirmatory Phase 3 clinical trial (FLASH2) for HyBryte™ in early-stage CTCL patients.. The FLASH2 trial will replicate the double-blind, placebo-controlled design of the successful Phase 3 FLASH study..

Is SOLIGENIX, INC. a risky investment based on this filing?

Based on this DEF 14A, SOLIGENIX, INC. presents a moderate-risk profile. The company's success hinges on the ongoing FDA discussions and the eventual outcome of the confirmatory Phase 3 trial, which carries inherent clinical and regulatory risks.

What should investors do after reading SOLIGENIX, INC.'s DEF 14A?

Monitor FDA feedback on the Phase 3 trial design and track progress on the FLASH2 study enrollment and results. The overall sentiment from this filing is bullish.

Risk Factors

  • Regulatory Approval Risk [high — regulatory]: The success of HyBryte™ is contingent upon obtaining marketing approval from regulatory bodies like the FDA and EMA, which involves rigorous clinical trials and review processes.
  • Financing and Cash Burn [medium — financial]: The company's ability to fund ongoing clinical trials and operations depends on its access to capital, which can be challenging for development-stage biopharmaceutical companies.
  • Market Acceptance and Competition [medium — market]: Even if approved, HyBryte™ must compete with existing treatments and gain acceptance from physicians and patients in the CTCL market.

Key Dates

  • 2024-04-29: Filing Date — Definitive Proxy Statement filed

Glossary

HyBryte™
Synthetic hypericin, a potential treatment for CTCL. (Key drug candidate central to the company's pipeline advancement.)
CTCL
Cutaneous T-cell lymphoma, a type of non-Hodgkin lymphoma affecting the skin. (The primary disease indication Soligenix is targeting with HyBryte™.)
FLASH2
A confirmatory Phase 3 clinical trial for HyBryte™ in early-stage CTCL patients. (The next critical step in seeking regulatory approval for HyBryte™.)

Filing Stats: 4,617 words · 18 min read · ~15 pages · Grade level 14.7 · Accepted 2024-04-29 16:01:21

Key Financial Figures

  • $0.001 — f record of our common stock, par value $0.001 per share ("Common Stock"), at the clos

Filing Documents

Security Ownership of Principal Stockholders and Management

Security Ownership of Principal Stockholders and Management 35 Equity Compensation Plan Information 37 Executive Officers 38

Executive Compensation

Executive Compensation 40 Overview of 2023 Executive Compensation Program 40

Executive Compensation Review

Executive Compensation Review 40 Summary Compensation 41 Employment and Severance Agreements 41 Outstanding Equity Awards at Fiscal Year-End 43 Pay Versus Performance 44 Compensation of Directors 46 Consideration and Determination of Executive and Director Compensation 46 Compensation Committee Interlocks and Insider Participation in Compensation Decisions 47 Transactions with Related Persons 47 Stock Performance Graph 49 Other Matters 50 Electronic Delivery of Proxy Materials 52 PURPOSE OF THESE MATERIALS: This Proxy Statement has been prepared and is distributed by the board of directors (the "Board of Directors") of Soligenix, Inc. in connection with the solicitation of proxies for the Annual Meeting of Stockholders (the "Annual Meeting") to be held at 9:00 a.m., Eastern Daylight Time, on Thursday, May 23, 2024, and any adjournment or postponement thereof for the purposes set forth in the accompanying Notice of Annual Meeting of Stockholders. ACCESS THE MEETING: The Annual Meeting will be held entirely online. Stockholders may participate in the Annual Meeting by visiting the following website: www.virtualshareholdermeeting.com/ sngx2024 . To participate in the Annual Meeting, you will need the 16-digit control number included on your proxy card or on the instructions that accompanied your proxy materials. MORE INFORMATION: Unless the context indicates otherwise, as used in this Proxy Statement, the terms "we," "us" "our" and "our Company" refer to Soligenix, Inc. This Proxy Statement and the accompanying form of proxy will be distributed to stockholders on or about April 30, 2024. Our Annual Report on Form 10-K for the year ended December 31, 2023 (which does not form a part of the proxy solicitation materials) is being distributed concurrently herewith to stockholders. SOLIGENIX, INC. 29 Emmons Drive, Suite B-10 Princeton, New Jersey 08540 TABLE OF CONTENTS Proxy Guide About Us Soligenix, In

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.